Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT04324151
Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
Sponsor: Hunan Province Tumor Hospital
View on ClinicalTrials.gov
Summary
This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Official title: Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
70
Start Date
2020-03-24
Completion Date
2025-03-24
Last Updated
2024-09-19
Healthy Volunteers
No
Conditions
Locations (1)
Yongchang Zhang
Changsha, Hunan, China